Extended Data Fig. 8: Characterization of ADAM12⁺ cells in human tumors.

(a) Expression of ADAM12 transcript in single-cell RNAseq from human colorectal cancer patients⁸⁴ (N = 62 patients, total 371,223 cells). Clustering = All cells (tSNE); On x axis, all cell subsets from the tumors are represented (88), and the major clusters expressing ADAM12 are highlighted (annotation from Pelka et al.⁸⁴; Pericyte_cS19, max: 3.314; q3: 1.08525, median: 0; CAF_cS28, max: 4.485, q3:1.50125, median: 0.558). (b) Expression of ADAM12 transcripts in single-cell RNAseq from melanoma patients⁸⁵ (N = 31 melanoma tumors, total 39744 cells). Clustering = Non-malignant cells from melanoma tumors (CAF, max: 5.2823, q3: 3.0613, mean: 1.49153, median: 0). (c) Expression of ADAM12 transcripts in single-cell RNAseq from human PDAC⁸⁶ (N = 24 primary untreated PDAC tumors, 41986 cells). Clustering= All cells (see Methods). (d) tSNE representation of ADAM12 expression in human PDAC as described in Peng et al.⁸⁶ (top panel) and transcriptional signature of activated stromal PDAC subtype as described in Puleo et al.⁶⁵ (lower panel). Two-sided Pearson’s Correlation Coefficient (R) was measured between ADAM12 expression and the activated stromal subtype signature (displayed in the tSNE panel). (e) Expression of the indicated transcripts in scRNAseq dataset from d. (f) Clinicopathologic characteristics of patients from the TCGA_PRAD project studied in Fig. 6. Patients (N = 455) were grouped according to their expression of ADAM12, as described in Methods. The associations were tested using two-sided Pearson chi2 test for categorical variables and the Mann–Whitney U test for continuous variables. Pathological classification: T – Extent of the primary tumor; N – Absence or presence and extent of regional lymph node metastases; M – Absence or presence of distant metastases. In a,b, data were visualized on the Single Cell portal of The Broad Institute of MIT and Harvard (https://singlecell.broadinstitute.org/single_cell).